1. Home
  2. UNTY vs DSGN Comparison

UNTY vs DSGN Comparison

Compare UNTY & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unity Bancorp Inc.

UNTY

Unity Bancorp Inc.

HOLD

Current Price

$56.20

Market Cap

523.6M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

SELL

Current Price

$10.27

Market Cap

579.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
UNTY
DSGN
Founded
1991
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
523.6M
579.9M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
UNTY
DSGN
Price
$56.20
$10.27
Analyst Decision
Buy
Buy
Analyst Count
2
3
Target Price
$65.00
$15.00
AVG Volume (30 Days)
48.8K
298.1K
Earning Date
01-13-2026
03-09-2026
Dividend Yield
1.07%
N/A
EPS Growth
39.66
N/A
EPS
5.67
N/A
Revenue
$127,871,000.00
N/A
Revenue This Year
$11.57
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
$9.90
N/A
Revenue Growth
23.99
N/A
52 Week Low
$36.65
$2.60
52 Week High
$57.24
$10.97

Technical Indicators

Market Signals
Indicator
UNTY
DSGN
Relative Strength Index (RSI) 64.36 54.22
Support Level $55.20 $9.54
Resistance Level $57.00 $10.75
Average True Range (ATR) 1.59 0.69
MACD 0.35 -0.04
Stochastic Oscillator 97.54 59.69

Price Performance

Historical Comparison
UNTY
DSGN

About UNTY Unity Bancorp Inc.

Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: